Welcome to our dedicated page for Barinthus Biotherapeutics plc news (Ticker: vacc), a resource for investors and traders seeking the latest updates and insights on Barinthus Biotherapeutics plc stock.
Barinthus Biotherapeutics (NASDAQ: BRNS) is a clinical-stage innovator developing T cell immunotherapies for chronic diseases and cancer. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory developments, and scientific breakthroughs.
Our curated collection features verified updates on Barinthus’ pipeline programs including VTP-300 for Hepatitis B and VTP-200 targeting HPV. Track progress across all development stages – from preclinical research to late-phase trials – with timely reports on study initiations, data readouts, and partnership announcements.
Key focus areas include updates on the company’s proprietary platforms like ChAdOx and MVA vector systems, financial position updates, and strategic collaborations. Recent highlights feature Phase 2 HBV trial developments and manufacturing scale-up initiatives.
Bookmark this page for structured access to Barinthus Biotherapeutics’ latest advancements in immune-guided therapies. All content is sourced from company filings and official communications to ensure reliability.
Vaccitech plc (NASDAQ: VACC) announced the publication of results from the Phase 1 clinical trial of its ChAdOx1 MERS vaccine candidate in The Lancet Microbe. Conducted in Saudi Arabia, this trial demonstrated that the vaccine was generally well tolerated, with robust immune responses observed over a six-month period. The results support advancing the vaccine to Phase 2 development. MERS, with a 34% fatality rate, poses a significant global health threat, highlighting the importance of this vaccine's ongoing development.
Vaccitech plc (NASDAQ: VACC) announced two poster presentations at AASLD’s Liver Meeting® 2021, showcasing clinical data for VTP-300, its immunotherapeutic for chronic hepatitis B virus (HBV) infection. The presentations include interim results from a Phase 1 study on ChAdOx1-HBV and a Phase 1b/2a study combining ChAdOx1/MVA vaccination with low-dose nivolumab. These findings will be presented virtually from November 12-15, 2021, highlighting progress in developing innovative treatments for HBV.
Vaccitech plc (NASDAQ: VACC), a biopharmaceutical firm, announced an update on its Phase 1b/2a trial for chronic hepatitis B (CHB) treatment, VTP-300. Chief Scientific Officer, Tom Evans, will present findings at The World Vaccine Congress Europe on October 21, 2021, in Barcelona. The talk will cover preclinical and clinical data ahead of two presentations at AASLD’s The Liver Meeting 2021 in November. The presentation will be available on Vaccitech’s website at 7:30 a.m. EDT.
AstraZeneca will present data on its COVID-19 and RSV pipeline at the IDWeek 2021 conference, showcasing the long-acting antibody AZD7442 and its potential for COVID-19 prevention. Phase III PROVENT trial results indicate AZD7442 may reduce symptomatic COVID-19 risk significantly, particularly in vulnerable populations. The analysis will also cover the efficacy of AZD1222 in preventing asymptomatic infections and the recently developed nirsevimab for RSV protection in infants. Preliminary findings suggest that AZD7442 neutralizes emerging SARS-CoV-2 variants and regulatory submissions for emergency use authorization are forthcoming.
Vaccitech plc (NASDAQ: VACC), a biopharmaceutical firm focused on immunotherapeutics and vaccines, has announced upcoming presentations by CEO Bill Enright at key investment conferences in September. He will speak at the Morgan Stanley Healthcare Conference on September 9, in a fireside chat at 11:45 a.m. EDT, available via webcast. Additionally, he will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13 to 15, with an on-demand presentation and a panel discussion on pandemic preparedness.
Vaccitech plc (NASDAQ: VACC) reported its second quarter financial results for 2021, marking their first quarter as a public company following an IPO in May. The company raised $110.5 million through this IPO and an additional $125.3 million from a Series B financing. As of June 30, 2021, Vaccitech had cash and equivalents of $243.6 million, sufficient to fund operations into H1 2024. R&D expenses increased to $4.5 million, while general and administrative costs rose significantly to $12.4 million, leading to a net loss of $15.9 million, or $0.64 per share.
Vaccitech plc (NASDAQ: VACC), a biopharmaceutical company focused on immunotherapeutics and vaccines, will have CEO Bill Enright present at the William Blair Biotech Focus Conference 2021 on July 15 at 1 p.m. EDT. A live webcast of the presentation will be available on Vaccitech's website, with a replay accessible afterward. The company's proprietary platform includes advanced adenoviral vectors and has a strong pipeline in treating infectious diseases and cancer, including a co-invented COVID-19 vaccine now licensed to AstraZeneca.
Vaccitech plc (NASDAQ: VACC) reported its financial results for Q1 2021, highlighting significant corporate developments. Key achievements included closing a Series B financing round of $168 million and initiating patient dosing in two lead therapeutic programs targeting HPV and HBV. As of March 31, 2021, the company's cash position was $155.9 million, bolstered by a successful IPO that raised $110.5 million. However, the company posted a net loss of $15.3 million, sharply increasing from $3.8 million in Q1 2020 due to higher R&D expenses and losses related to convertible loan notes.
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical firm, announced that CEO Bill Enright will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 11:00 AM EDT. A live webcast will be available on the Vaccitech website, with a replay posted afterward. Vaccitech specializes in developing immunotherapeutics and vaccines for infectious diseases and cancer, utilizing innovative platforms like ChAdOx1 and ChAdOx2. The company co-invented a COVID-19 vaccine in collaboration with the University of Oxford, licensed to AstraZeneca.
Vaccitech plc (NASDAQ: VACC) has closed its initial public offering, selling 6,500,000 American Depositary Shares (ADSs) at $17.00 per ADS, yielding gross proceeds of approximately $110.5 million. Trading began on the Nasdaq Global Market on April 30, 2021. The offering was managed by leading financial institutions including Morgan Stanley, Jefferies, Barclays, and William Blair. Vaccitech specializes in developing innovative vaccines and immunotherapeutics for infectious diseases and cancer, leveraging proprietary technology from its broad therapeutic pipeline.
